EP3522891A4 - Pharmazeutische kombinationen aus einem histon-deacetylase-hemmer und proteasom-hemmer oder immunomodulator zur behandlung von blutkrebserkrankungen - Google Patents

Pharmazeutische kombinationen aus einem histon-deacetylase-hemmer und proteasom-hemmer oder immunomodulator zur behandlung von blutkrebserkrankungen Download PDF

Info

Publication number
EP3522891A4
EP3522891A4 EP17858740.8A EP17858740A EP3522891A4 EP 3522891 A4 EP3522891 A4 EP 3522891A4 EP 17858740 A EP17858740 A EP 17858740A EP 3522891 A4 EP3522891 A4 EP 3522891A4
Authority
EP
European Patent Office
Prior art keywords
inhibitor
treatment
histone deacetylase
hematological cancer
pharmaceutical combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17858740.8A
Other languages
English (en)
French (fr)
Other versions
EP3522891A1 (de
Inventor
Soo Jin Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chong Kun Dang Corp
Original Assignee
Chong Kun Dang Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chong Kun Dang Corp filed Critical Chong Kun Dang Corp
Publication of EP3522891A1 publication Critical patent/EP3522891A1/de
Publication of EP3522891A4 publication Critical patent/EP3522891A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP17858740.8A 2016-10-04 2017-09-29 Pharmazeutische kombinationen aus einem histon-deacetylase-hemmer und proteasom-hemmer oder immunomodulator zur behandlung von blutkrebserkrankungen Withdrawn EP3522891A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160127767A KR102002581B1 (ko) 2016-10-04 2016-10-04 혈액암 치료를 위한 hdac 저해제 및 프로테아좀 억제제 또는 면역조절성 약물을 포함하는 약학적 조합물
PCT/KR2017/011015 WO2018066946A1 (en) 2016-10-04 2017-09-29 Pharmaceutical combinations of histone deacetylase inhibitor and proteasome inhibitor or immunomodulatory drug for the treatment of hematological cancer

Publications (2)

Publication Number Publication Date
EP3522891A1 EP3522891A1 (de) 2019-08-14
EP3522891A4 true EP3522891A4 (de) 2020-04-15

Family

ID=61832016

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17858740.8A Withdrawn EP3522891A4 (de) 2016-10-04 2017-09-29 Pharmazeutische kombinationen aus einem histon-deacetylase-hemmer und proteasom-hemmer oder immunomodulator zur behandlung von blutkrebserkrankungen

Country Status (11)

Country Link
EP (1) EP3522891A4 (de)
JP (2) JP2019529562A (de)
KR (1) KR102002581B1 (de)
CN (1) CN109789138A (de)
AU (1) AU2017338564B2 (de)
BR (1) BR112019006633A2 (de)
CA (1) CA3038019A1 (de)
MX (1) MX2019003907A (de)
RU (1) RU2721409C1 (de)
WO (1) WO2018066946A1 (de)
ZA (1) ZA201902340B (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7415973B2 (ja) 2021-02-12 2024-01-17 信越化学工業株式会社 化学増幅ポジ型レジスト組成物及びレジストパターン形成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ552865A (en) * 2004-07-28 2009-09-25 Janssen Pharmaceutica Nv Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
EP2361619A1 (de) * 2005-11-10 2011-08-31 TopoTarget UK Limited Histone Deacetylase (hdac) Inhibitoren (pxd-101) zur Behandlung von hämatologischen Krebserkrankungen
AU2007296256B2 (en) * 2006-09-15 2013-05-30 Janssen Pharmaceutica Nv Histone deacetylase inhibitors with combined activity on class-I and class-IIB histone deacetylases in combination with proteasome inhibitors
US20120020876A1 (en) * 2009-01-23 2012-01-26 Kenneth Paul Olive Hedgehog pathway inhibitors
KR101168801B1 (ko) * 2009-03-27 2012-07-25 주식회사종근당 신규한 하이드록사메이트 유도체, 이의 제조방법, 및 이를 함유하는 약제학적 조성물
WO2010124009A2 (en) * 2009-04-21 2010-10-28 Schering Corporation Fully human anti-vegf antibodies and methods of using
US8610434B2 (en) 2011-07-21 2013-12-17 ColdEdge Technologies, Inc. Cryogen-free cooling system for electron paramagnetic resonance system
WO2013021032A1 (en) * 2011-08-11 2013-02-14 Janssen Pharmaceutica Nv Histone deacetylase inhibitors in combination with proteasome inhibitors and dexamethasone
EP2882442B1 (de) * 2012-08-09 2021-06-09 Celgene Corporation Verfahren zur krebsbehandlung mit (3-(4-(4-(morpholinomethyl)benzyl)oxy-)1-oxoisoindolin-2-yl-)piperidin-2,6-dion
US20150105358A1 (en) * 2013-10-11 2015-04-16 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase inhibitors and immunomodulatory drugs
KR101689394B1 (ko) * 2013-12-12 2016-12-23 주식회사 종근당 신규한 선택적인 히스톤탈아세틸화 효소 억제제로서의 아자인돌 유도체 및 이를 포함하는 약제학적 조성물

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "A Phase 1, Open-Label, Multi-Center Study of Alteminostat (CKD-581) in Combination with Lenalidomide and Dexamethasone in Patients with Previously Treated Multiple Myeloma (MM) | Blood | American Society of Hematology", 13 November 2019 (2019-11-13), XP055674271, Retrieved from the Internet <URL:https://ashpublications.org/blood/article/134/Supplement_1/1847/427755/A-Phase-1-OpenLabel-MultiCenter-Study-of> [retrieved on 20200306] *
CHANSU LEE ET AL: "Abstract 1695: CKD-581, a novel histone deacetylase inhibitor, synergistically enhances Bortezomib cytotoxicity in multiple myeloma cells", EXPERIMENTAL AND MOLECULAR THERAPEUTICS, 30 September 2014 (2014-09-30), pages 1695 - 1695, XP055673884, DOI: 10.1158/1538-7445.AM2014-1695 *
JONATHAN L. KAUFMAN ET AL: "Histone Deacetylase Inhibitors in Multiple Myeloma: Rationale and Evidence for Their Use in Combination Therapy", CLINICAL LYMPHOMA MYELOMA AND LEUKEMIA, vol. 13, no. 4, 17 June 2013 (2013-06-17), pages 370 - 376, XP055370013, ISSN: 2152-2650, DOI: 10.1016/j.clml.2013.03.016 *
See also references of WO2018066946A1 *

Also Published As

Publication number Publication date
KR102002581B1 (ko) 2019-07-22
BR112019006633A2 (pt) 2019-07-02
ZA201902340B (en) 2020-08-26
JP2021020953A (ja) 2021-02-18
KR20180037507A (ko) 2018-04-12
MX2019003907A (es) 2019-08-05
AU2017338564B2 (en) 2020-07-09
AU2017338564A1 (en) 2019-05-02
CA3038019A1 (en) 2018-04-12
JP2019529562A (ja) 2019-10-17
WO2018066946A1 (en) 2018-04-12
CN109789138A (zh) 2019-05-21
RU2721409C1 (ru) 2020-05-19
EP3522891A1 (de) 2019-08-14

Similar Documents

Publication Publication Date Title
EP3777888A4 (de) Pharmazeutische zusammensetzung zur behandlung und/oder prävention von krebs
EP3370748A4 (de) Therapeutische mikrobiota zur behandlung und/oder vorbeugung von lebensmittelallergie
EP3533466A4 (de) Pharmazeutische zusammensetzung zur krebsbehandlung und/oder vorbeugung
EP3076973A4 (de) Kombinationen aus histondeactylaseinhibitoren und immunmodulatorischen arzneimitteln
EP3031826A4 (de) Pharmazeutische zusammensetzung zur behandlung und/oder prävention von krebs
EP3580560A4 (de) Verfahren zur erkennung und behandlung von lungenkrebs
EP3458159A4 (de) Zusammensetzungen und verfahren zur prävention und behandlung von mitochondrialen myopathien
EP3436002A4 (de) Pharmazeutische kombinationen zur behandlung von krebs
EP3694832A4 (de) Pharmazeutische formulierung mit verlängerter freisetzung und verfahren zur behandlung
EP3592731A4 (de) Inhibitoren von malt1 und verwendungen davon
EP3448421A4 (de) Verfahren und zusammensetzungen zur vorbeugung und behandlung von chirurgischen verklebungen
EP3615056A4 (de) Verfahren und mittel zur erkennung und behandlung von krebs
EP3694523A4 (de) Methoden und substanzen zur prävention und behandlung von neurodegenerativen erkrankungen
EP3487492A4 (de) Verwendung von eribulin- und histon-deacetylase-inhibitoren zur behandlung von krebs
EP3544612A4 (de) Pharmazeutische kombinationen mit einem histondeacetylaseinhibitor und einem cd38-inhibitor und verfahren zur verwendung davon
EP3565549A4 (de) Selektive histondeacetylaseinhibitoren zur behandlung von menschlichen erkrankungen
IL266486A (en) Pharmaceutical preparations and methods for cancer treatment
EP3532054A4 (de) Pharmazeutische kombinationen mit einem histondeacetylasehemmer und epothilon sowie verfahren zur verwendung davon
EP3468559A4 (de) Verfahren zur verwendung und pharmazeutische kombinationen von hdac-hemmern mit bet-hemmern
EP3535275A4 (de) Pharmazeutische kombinationen mit einem histondeacetylaseinhibitor und einem bcl-2-inhibitor und verfahren zur verwendung davon
EP3532065A4 (de) Pharmazeutische kombinationen mit einem histondeacetylaseinhibitor und einem aurora-kinase-inhibitor und verfahren zur verwendung davon
EP3468540A4 (de) Pharmazeutische zusammensetzungen und verfahren zur schmerzbehandlung
EP3849992A4 (de) Cd73-inhibitoren und ihre pharmazeutischen verwendungen
EP3503885A4 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung
EP3458444A4 (de) Histon-deacetylase-6-hemmer und verwendung davon

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190314

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20200318

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/416 20060101ALI20200312BHEP

Ipc: A61K 31/454 20060101ALI20200312BHEP

Ipc: A61P 35/00 20060101ALI20200312BHEP

Ipc: A61K 31/56 20060101ALI20200312BHEP

Ipc: A61K 31/573 20060101ALI20200312BHEP

Ipc: A61K 38/00 20060101ALI20200312BHEP

Ipc: A61K 31/496 20060101AFI20200312BHEP

Ipc: A61K 31/69 20060101ALI20200312BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20210216

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20230203

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20230614